Investigational cell therapy for recurrent high-grade brain tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests an experimental cell therapy (MT027) for people with high-grade brain tumors that have come back or stopped responding to treatment. It targets a protein called B7-H3 found on tumor cells, aiming to attack the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have a confirmed high-grade glioma (grade 3 or 4) that has progressed or returned after standard treatment.
- Your tumor tests positive for a protein called B7-H3 (checked on a tissue sample).
- You have at least one brain tumor that can be measured on an MRI.
- Your cancer has not spread to the brainstem, spinal cord, or outside the brain.
- You have not had CAR-T cell therapy before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called TX103 CAR-T cells for people with a grade 4 glioma (like glioblastoma) that has come back or gotten worse after standard treatment. The therapy uses your own immune cells that are specially trained to attack a marker called B7-H3 found on tumor cells.
This trial tests a new treatment that combines a specially designed virus to attack tumor cells with an immunotherapy drug to help the immune system fight the cancer. It is for people whose high-grade glioma (a type of brain tumor) has come back after standard treatment.
This trial tests a two-part treatment: an injected virus (DB107-RRV) plus an oral medication (DB107-FC) for people whose high-grade glioma (a type of brain tumor) has come back. The virus is designed to deliver a gene that makes the tumor sensitive to the oral drug, which then helps kill the cancer cells.
This trial is testing a new type of cell therapy called CAR-T that targets a marker (B7-H3) on brain tumor cells. It is for people with grade 4 gliomas that have returned after standard treatment, and it aims to see if this treatment can help control the tumor.
This trial tests a new cell therapy (QH104) for people with an aggressive brain tumor called high-grade glioma that has come back or worsened after standard treatment. The therapy targets a specific protein (B7-H3) on tumor cells to try to fight the cancer.
This trial tests a new kind of cell therapy called CAR-T, made from donor cells, to treat glioblastoma that has come back. The treatment targets a specific marker on the tumor (B7H3) and is injected into the brain to attack the cancer cells.
Hear when a new High Grade Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.